A Chart Review Study of Patients With Haemophilia A With Inhibitors Treated With rFVIIIFc (Elocta®) for Immune Tolerance Induction
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Efmoroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Sponsors Swedish Orphan Biovitrum
Most Recent Events
- 11 Jan 2023 Status changed from active, no longer recruiting to completed.
- 29 Oct 2020 Planned number of patients changed from 50 to 45.
- 29 Oct 2020 Planned End Date changed from 6 Nov 2023 to 30 Dec 2022.